New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
16:29 EDTGOOG, NVO, NDAQ, BBRY, SNY, AAPL, HEKOn The Fly: Closing Wrap
Stocks on Wall Street were slightly lower and traded in a narrow range during the session. Investors had little to react to on the domestic economic calendar and holidays in Asia also slowed the data flow from abroad... ECONOMIC EVENTS: In the U.S., no major economic data was reported. In Europe, a meeting of finance ministers of the countries using the euro convened, with the strength of the shared currency, how to handle a bailout for Cyprus and progress in Greece likely to be discussed. In Asia, Chinese and Japanese markets were closed for holidays... COMPANY NEWS: Shares of Apple (AAPL) rose $4.95, or 1.04%, to $479.93 amid rumors of a new "iWatch" that is under development and continued speculation around what, if anything, CEO Tim Cook may announce tomorrow in terms of capital return plans during his speech at the Goldman Sachs Technology and Internet Conference... Nasdaq (NDAQ) shares gained 91c, or 3.09%, to $30.38 after Charles Gasparino of Fox Business said the company held "going private" talks with Carlyle Group, though the report said talks are not ongoing... Google (GOOG) Chairman Eric Schmidt disclosed plans late Friday to sell 3.2M of the shares he holds, valued at $2.5B. Google fell as much as 1% during the session but closed down $2.95, or 0.38%, at $782.42... MAJOR MOVERS: Among notable gainers were shares of Sanofi (SNY), up $1.49, or 3.2%, to $48.01, after rival Novo Nordisk (NVO) received an FDA Complete Response Letter indicating that the company's insulin products will need additional tests before approval. Shares of Novo Nordisk fell $26.89, or 13.98%, to $165.40 following the FDA decision. Also lower were shares of Heckmann (HEK), down 45c, or 10.34%, to $3.90 after being downgraded to Underperform at Wedbush, and BlackBerry (BBRY), down 76c, or 4.61%, to $15.73 after a report said Home Depot (HD) would replace staff BlackBerry's with Apple's iPhone 4S... INDICES: The Dow was down 21.73, or 0.16%, to 13,971.24; the Nasdaq was down 1.87, or 0.06%, to 3,192.00; and the S&P 500 was down 0.92, or 0.06%, to 1,517.01.
News For AAPL;NDAQ;GOOG;SNY;NVO;HEK;BBRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 >>
January 25, 2016
19:20 EDTAAPLApple reshuffles India operations after 'deep discounting' in quarter, ET says
Subscribe for More Information
16:00 EDTAAPLOptions Update; January 25, 2016
Subscribe for More Information
14:18 EDTAAPLApple volatility increases into Q1 and outlook
Subscribe for More Information
14:17 EDTAAPLVIX methodology for Apple VXAPL +3% to 39.17 into Q1 & outlook
Subscribe for More Information
14:06 EDTAAPLApple technical comments ahead of earnings, potential bearish pattern
There is a potential bearish head and shoulders top, which is most easily seen on a 3-year chart. The neckline for the pattern is at the $100 area on a closing basis, and in recent sessions the pattern has been both active and inactive as price crossed that line. If the news is bearish, a breakdown below $100 would see the pattern become active. Downside potential for the pattern would be to the $70 to $66 area. If the news is a bullish surprise, and sentiment has turned negative on the name which could add to short-cover demand, the counter-reaction up may be as large as pattern suggests is possible on the downside. It could mean in time a retaking of the $130 area or higher. The life high for the shares is at $134.54.
12:59 EDTAAPLApple executives unsatisfied with progress of 'Project Titan,' AppleInsider says
Subscribe for More Information
12:53 EDTGOOGVine head Jason Toff to leave Twitter to join Google
Subscribe for More Information
10:55 EDTSNYRegeneron slips after analyst says sell to avoid risk from Amgen patent suit
Shares of Regeneron Pharmaceuticals (REGN) fell in morning trading after an analyst at Chardan downgraded the stock to Sell, citing risk from a patent lawsuit in which the biopharmaceutical company is involved. CHARDAN SAYS SELL: Chardan Capital Markets analyst Gbola Amusa downgraded Regeneron to Sell from Neutral this morning, while reducing his price target on shares to $400 from $525. In a note to clients, Amusa said he believes that Regeneron is likely to face significant risks from the upcoming patent infringement case for Praluent. The suit could be a key driver of the company's share price performance in the near future, the analyst said. Regeneron, along with its partner Sanofi (SNY), launched Praluent in the U.S. last year, after the October 2014 filing of a patent infringement suit by Amgen (AMGN) relating to patents for "monoclonal antibodies that bind PCSK9," Amusa noted. The analyst believes that since Regeneron and Sanofi "likely" infringe Amgen's patents for Repatha, the Regeneron-Sanofi partnership could seek to settle the ahead of the trial by agreeing to pay 10%-20% or more of royalties to Amgen for U.S. Praluent sales. Amusa said that "such an outcome we estimate could transfer roughly $750M of operating income per year to Amgen." Further, Amusa said that catalysts surrounding the patent infringement trial are "likely to play out from late February to late March," and concedes that "both sides have good reasons to settle this case for a reasonable royalty." INCREASING COMPETITION: Amusa also noted that he sees increasing competitive risks in 2016 to Regeneron's Eylea from Novartis (NVS) and its partner Ophthotech (OPHT), which continue to progress Fovista into Phase III trials in wet AMD. WHAT'S NOTABLE: Roth Capital upgraded Regeneron to Buy from Neutral on January 19, based on valuation, as the firm said shares do not reflect the value of the company's upcoming catalysts. The firm also raised its price target to $555 from $543. The same day, Credit Suisse initiated Regeneron with a Neutral rating and $552 target. PRICE TARGET: Regeneron slipped 1.4% to $476.02 in morning trading.
10:44 EDTGOOGAmazon eyeing tighter software team-ups with Android makers, Information says
Amazon (AMZN) is eyeing ways to create tighter software partnerships with Android phone makers, the Information reports, citing people briefed on different aspects of the discussions. The company has had talks over working with phone brands at a "factory level" to integrate its services with devices in a more complex way than just preloading apps, the report says. Such moves would help Amazon gain traction of influence over Android smartphone software, owned by Google (GOOG), the report says. Reference Link
10:03 EDTAAPLApple's iPhone 5se to likely come with faster A9/M9 chips, 9to5Mac reports
Subscribe for More Information
09:32 EDTAAPLApple Active equity options trading on open
Subscribe for More Information
07:54 EDTGOOGAlphabet volatility up into Q4, costs, income projects outside of core business
Subscribe for More Information
07:06 EDTAAPLApple volatility elevated into Q1 and outlook
Apple 1/29/16 call option implied volatility is at 57, February is at 38; compared to its 52-week range of 18 to 55, suggesting large near term price movement into the expected release of Q1 results on January 26.
06:44 EDTAAPLApple to release new iPhone, iPad Air 3 in 1H16, AppleInsider says
Apple is planning to launch a 4-inch iPhone as well as the iPad Air 3 in the first half of the year, AppleInsider reports, citing KGI analyst Ming-Chi Kuo. Reference Link
06:27 EDTGOOGGoogle's added transparency may make ad business seem more profitable, WSJ says
Subscribe for More Information
06:09 EDTGOOGYouTube hires Broock as 'Global VR Evangelist,' Re/code reports
Subscribe for More Information
05:51 EDTAAPLOptions expected to be active: TYC JCI TWTR SUNE AAPL PG HAL AMZN FB
Subscribe for More Information
January 24, 2016
19:10 EDTAAPL, GOOGDaimler CEO: Apple, Google farther along on car than assumed, Reuters says
Subscribe for More Information
15:27 EDTAAPLHead of Apple's car project stepping down, Bloomberg says
Subscribe for More Information
14:40 EDTGOOGCollapse in private tech could ripple into public markets, Barron's says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use